Breaking News, Collaborations & Alliances

Celltrion, CSL Enter Antibody Pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Celltrion, Inc. and CSL Ltd., an Australian biopharmaceutical company, have signed an agreement for the development and supply of CSL 360, an experimental monoclonal antibody for the treatment of acute myeloid leukemia (AML). CSL is currently conducting Phase I trials for the drug in Australia.     Celltrion, a Korean biopharma CMO, will provide process development expertise and supply clinical and commercial material to support the development program and commercialization of the drug. Under...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters